NAS will utilize the collected data to support Phase 2 initiatives advancing NAS150 as an RA treatment alternative. The Company’s Platform of Inflammatory Reducing Therapeutics is also intended to be leveraged for the treatment of other autoimmune conditions including Multiple Sclerosis Binghamton, NY – January 5th 2022 — New Amsterdam Sciences, a privately held bioscience company, […]